This is a preview of subscription content, log in via an institution to check access.
Notes
Midostaurin
Reference
Tremblay G, et al. Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. European Journal of Health Economics : 22 Jan 2020. Available from: URL: https://doi.org/10.1007/s10198-019-01149-9
Rights and permissions
About this article
Cite this article
Midostaurin cost effective for FLT3-mutated AML. PharmacoEcon Outcomes News 846, 18 (2020). https://doi.org/10.1007/s40274-020-6557-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6557-3